Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Asset Writedowns and Impairment: 2012-2023

Historic Asset Writedowns and Impairment for Amphastar Pharmaceuticals (AMPH) over the last 5 years, with Dec 2023 value amounting to $2.7 million.

  • Amphastar Pharmaceuticals' Asset Writedowns and Impairment was N/A to $114,000 in Q2 2016 from the same period last year, while for Jun 2016 it was $463,000, marking a year-over-year change of. This contributed to the annual value of $2.7 million for FY2023, which is N/A change from last year.
  • According to the latest figures from FY2023, Amphastar Pharmaceuticals' Asset Writedowns and Impairment is $2.7 million, which was up 1,210.68% from $206,000 recorded in FY2015.
  • Over the past 5 years, Amphastar Pharmaceuticals' Asset Writedowns and Impairment peaked at $2.7 million during FY2023, and registered a low of $2.7 million during FY2023.
  • In the last 1 years, Amphastar Pharmaceuticals' Asset Writedowns and Impairment had a median value of $2.7 million in 2023 and averaged $2.7 million.